dry AMD

1 stories · following the connections

Business

Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor

By Nasdaq OMXFeb 11, 2016, 11:05 AM UTC